A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorXinqiao Hospital of Chongqing
About this trial
In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy
Eligibility criteria
Qualifiers
Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.
the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.
the stage IV according to the eighth edition of IASLC.
PS 0-2, the expected survival > 3 months.
Disqualifiers
the patients' compliance was poor, which violated the rules of the trial;
the patients with severe dysfunction of vital organs (heart, liver and kidney) ;
the patients with other malignant tumors;
the researchers considered that the patients should not participate in other conditions of the trial.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov